Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Recombinant alpha-1-microglobulin : A potential treatment for preeclampsia

Gunnarsson, Rolf ; Åkerström, Bo LU ; Hansson, Stefan R. LU orcid and Gram, Magnus LU orcid (2017) In Drug Discovery Today 22(4). p.736-743
Abstract

Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the... (More)

Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the potential to become the first specific therapy for preeclampsia.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Drug Discovery Today
volume
22
issue
4
pages
736 - 743
publisher
Elsevier
external identifiers
  • scopus:85009781743
  • pmid:27988357
ISSN
1359-6446
DOI
10.1016/j.drudis.2016.12.005
language
English
LU publication?
yes
id
4b8c0233-bf05-45e3-901d-ac35a45cb5bd
date added to LUP
2017-03-14 10:11:41
date last changed
2024-05-26 11:55:45
@article{4b8c0233-bf05-45e3-901d-ac35a45cb5bd,
  abstract     = {{<p>Preeclampsia is a serious pregnancy-specific condition, affecting 10 million women annually worldwide. No specific treatment is currently available. Recent studies have demonstrated abnormal production and accumulation of free fetal hemoglobin in the preeclamptic placenta, and identified subsequent leakage into the maternal circulation as an important factor in the development of preeclampsia. A recombinant version of alpha-1-microglobulin, an endogenous well-characterized heme and radical scavenger, has been developed. Intravenous administration of recombinant alpha-1-microglobulin in animal models has been proved to eliminate or significantly reduce the manifestations of preeclampsia. Recombinant alpha-1-microglobulin has the potential to become the first specific therapy for preeclampsia.</p>}},
  author       = {{Gunnarsson, Rolf and Åkerström, Bo and Hansson, Stefan R. and Gram, Magnus}},
  issn         = {{1359-6446}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{736--743}},
  publisher    = {{Elsevier}},
  series       = {{Drug Discovery Today}},
  title        = {{Recombinant alpha-1-microglobulin : A potential treatment for preeclampsia}},
  url          = {{http://dx.doi.org/10.1016/j.drudis.2016.12.005}},
  doi          = {{10.1016/j.drudis.2016.12.005}},
  volume       = {{22}},
  year         = {{2017}},
}